Since OpenAI released ChatGPT in 2022, launching a new arms race in the field of generative AI, several industries have been scrambling to figure out how large language model systems could make their workflows more efficient and productive.
The world of pharmaceuticals is not immune. The promises of AI in pharma are plentiful and global groups are investing billions of dollars to outcompete one another, while AI-first start-ups are sprouting up in the industry.
The pharma sector has long embraced technology to improve the process of discovering and delivering new treatments to patients. “In the research space, AI has been used for decades in the industry,” says Thorsten Rall, global industry lead for life sciences at Capgemini, the IT services group. “Pharma is a data-rich environment and applications like AI for [identifying treatment targets] and molecule design have been around for a while and deployed quite broadly.”